Since new adjuvant treatments in completely resected stage II-IV melanoma have demonstrated a significant impact on relapse-free survival and overall survival in patients with BRAFV600-mutant melanoma [48,49], the early detection of a BRAF V600 mutation in primary tumors (pT2b-pT4) or SLN is crucial, even at an early tumor stage [4]. Here, BRAF is linked to neoplasm.